PTU - Polskie Towarzystwo Urologiczne

LECZENIE ZAAWANSOWANEGO RAKA STERCZA (RAKA STERCZA Z PRZERZUTAMI ODLEGŁYMI) CZĘŚĆ II. KLASYCZNA MANIPULACJA HORMONALNA
Artykuł opublikowany w Urologii Polskiej 1996/49/3.

autorzy

Andrzej Borkowski
Katedra i Klinika Urologii A.M. w Warszawie
Kierownik Kliniki: prof. dr hab. med. Andrzej Borkowski

słowa kluczowe

zaawansowany rak stercza leczenie rokowanie

piśmiennictwo

  1. (1) Andersson /.: Estrogens and estramustine phosphate. W monografii: The medical
  2. management of prostate cancer. L. Denis edit. Springer, 1988, str. 37.
  3. (2) Botto H., Richard F., Mathieu K, De MouzonJ.: Randomised multicenter trial: Trip-
  4. torelin vs surgical castration, long term results and Prognostic factors. Proceedings
  5. of 4th international Symposium on recent advances in urological cancer diagnosis
  6. and treatment. Paris 1994. S.C.I. edit., str. 307.
  7. (3) Byar D.P.: The Veterans Administration cooperative urological research group's
  8. studies on cancer of the prostate. Cancer. 1973, 32, 1126.
  9. (4) Coffey D.S.: Prostate cancer: An overview of an increasing dilemma. Cancer. 1993,
  10. 71, 880.
  11. (5) Denis L., Mahler C: Le traitement du cancer prostatique. Cours superieur franco-
  12. phone de cancerologie European School of Urology. Edit. I.CI. Montligeon 1991
  13. str. 119.
  14. (6) Fourcade R. O.: Is it still justified to withold hormonal treatment until symptoms
  15. are bothersome? Proceedings of 4th international Symposium on recent advances in
  16. urological cancer diagnosis and treatment. Paris 1994, S.C.I. edit., str. 133.
  17. (7) Makler C; Is disease tlare a problem? Cancer Suppl., 1993, 72, 3799.
  18. (8) Oosterhof C.O.N., Debruyne F.M.J.: Les analogues de la LHRH. Memoires de Co-
  19. urs superieur francophone de cancerologie European School of Urology. Edit. I.CI.
  20. Montligeon 1991, str. 73.
  21. (9) Pontes J.E.: New approaches to the treatment of hormonally unresponsive prostate
  22. cancer. A review. Proceedings of 4th international Symposium on recent advances
  23. in urological cancer diagnosis and treatment. S. C. I. edit., Paris, 1994, str. 368.
  24. (10) Ruutu M, Aro J., Rannikko S.\ High dose polyestradiol fosfate versus orchiectomy
  25. for prostatic cancer patients with high or low endogenous estradiol. Proceedings of
  26. 4th international Symposium on recent advances in urological cancer diagnosis and
  27. treatment. Paris, 1994, S. C. 1. edit., str. 340.
  28. (11) Sehroder RH.: Adjuyant endocrine treatment of prostatic cancer. European Urolo-
  29. gy Update Series. EBU edit., 1993, 2, 24.
  30. (12) Smith RH.: Controversial topics in prostatic cancer. Urol. Pol., 1994, 47, 4.
  31. (13) Steg A., Zerbib M., ConquvS.: Les estrogens ont-ils encore une place dans le traite-
  32. ment du cancer de la prostate. Cours superiere francophone de cancerologie Euro-
  33. pean School of Urology. Montligeon, 1991, I. C. I. edit., str. 69.
  34. (14) Stege R., Henriksson R, Pousette A., Carlstrom K.: Estradurin, a high dose i.m.
  35. depot estrogen for safe first line treatment on advanced prostatic cancer. Procee-
  36. dings of 4th international Symposium on recent advances in urological cancer dia-
  37. gnosis and treatment. Paris, 1994, S. C. I. edit., str. 343.
  38. (15) YACURG: Carcinoma of the prostate: treatment comparisons. J. Urol., 1967, 98,
  39. 516.